<p>肿瘤研究所公司（NASDAQ:TOI - 获取免费报告）主要股东 Jorey Chernett 于 5 月 19 日星期二收购了 5,000 股肿瘤研究所股票。每股平均购买价格为 4.05 美元，总交易额为 20,250.00 美元。完成购买后，该内部人士直接持有公司 10,534,358 股股票，价值 42,664,149.90 美元。此次交易使其持股比例增加了 0.05%。该交易已在与证券交易委员会的法律文件中披露，相关信息可通过 SEC 网站获取。持有公司至少 10% 股份的大股东需向 SEC 披露其交易情况。</p>
<p>获取 <strong>肿瘤研究所</strong> 的提醒：</p>
<p>Jorey Chernett 最近还进行了以下交易：</p>
<ul>
<li>5 月 20 日星期三，Jorey Chernett 购买了 33,500 股肿瘤研究所股票。每股平均成本为 4.07 美元，总交易额为 136,345.00 美元。</li>
<li>5 月 19 日星期二，Jorey Chernett 购买了 30,000 股肿瘤研究所股票。每股平均成本为 4.09 美元，总交易额为 122,700.00 美元。</li>
<li>4 月 9 日星期四，Jorey Chernett 购买了 20,000 股肿瘤研究所股票。每股平均成本为 3.10 美元，总交易额为 62,000.00 美元。</li>
<li>3 月 24 日星期二，Jorey Chernett 购买了 125,000 股肿瘤研究所股票。每股平均价格为 3.11 美元，总价值为 388,750.00 美元。</li>
<li>3 月 20 日星期五，Jorey Chernett 购买了 25,000 股肿瘤研究所股票。每股平均成本为 3.35 美元，总交易额为 83,750.00 美元。</li>
<li>3 月 17 日星期二，Jorey Chernett 购买了 75,000 股肿瘤研究所股票。每股平均成本为 3.42 美元，总交易额为 256,500.00 美元。</li>
<li>3 月 16 日星期一，Jorey Chernett 购买了 60,985 股肿瘤研究所股票。每股平均价格为 3.29 美元，总价值为 200,640.65 美元。</li>
<li>3 月 13 日星期五，Jorey Chernett 购买了 263,000 股肿瘤研究所股票。每股平均价格为 2.92 美元，总价值为 767,960.00 美元。</li>
</ul>
<h2>肿瘤研究所股票下跌 0.8%</h2>
<p>在周四的交易中，NASDAQ TOI 下跌 0.04 美元，报 4.17 美元。该公司的股票交易量为 358,184 股，而其平均交易量为 1,889,279 股。该公司的 50 日移动平均价格为 3.43 美元，200 日移动平均价格为 3.32 美元。该公司的市值为 4.1167 亿美元，市盈率为-11.26，贝塔值为 0.33。肿瘤研究所公司的 52 周低点为 2.02 美元，52 周高点为 4.88 美元。</p>
<p>肿瘤研究所（NASDAQ:TOI - 获取免费报告）最近于 5 月 7 日星期四发布了季度财报。公司报告每股收益（EPS）为-0.02 美元，超出分析师一致预期的-0.07 美元，超出幅度为 0.05 美元。该季度的收入为 1.4744 亿美元，而一致预期为 1.4210 亿美元。分析师平均预计肿瘤研究所公司在当前年度的每股收益为-0.2 美元。</p>
<h2>机构资金流入和流出</h2>
<p>一些机构投资者最近增加或减少了在该公司的持股。先锋集团（Vanguard Group Inc.）在第三季度将其在肿瘤研究所的持股增加了 6.2%。先锋集团目前持有 4,545,245 股该公司的股票，价值 15,863,000 美元，此前在该期间内又购买了 264,358 股。CenterBook Partners LP 在第四季度将其在肿瘤研究所的持股增加了 12.0%。CenterBook Partners LP 目前持有 3,029,312 股该公司的股票，价值 10,784,000 美元，此前在该期间内又收购了 324,662 股。Kanen Wealth Management LLC 在第四季度将其在肿瘤研究所的持股增加了 61.6%。Kanen Wealth Management LLC 目前持有 2,976,144 股该公司的股票，价值 10,712,000 美元，此前在该期间内又收购了 1,134,043 股。Balyasny Asset Management L.P.在第二季度将其在肿瘤研究所的持股增加了 17.3%。Balyasny Asset Management L.P.目前持有 2,518,337 股该公司的股票，价值 5,163,000 美元，此前在该期间内又购买了 371,005 股。最后，Josh Arnold Investment Consultant LLC 在第四季度将其在肿瘤研究所的持股增加了 1,104.3%。Josh Arnold Investment Consultant LLC 目前持有 2,459,809 股该公司的股票，价值 8,757,000 美元，此前在该期间内又购买了 2,255,559 股。36.86% 的股票由机构投资者和对冲基金持有。</p>
<h2>华尔街分析师预测增长</h2>
<p>几家券商最近对 TOI 发布了报告。Weiss Ratings 在 4 月 20 日星期一的研究报告中重申了对肿瘤研究所股票的 “卖出（d-）” 评级。B. Riley Financial 在 3 月 13 日星期五将肿瘤研究所的目标价格从 6.00 美元提高至 8.00 美元，并给予该公司 “买入” 评级。Needham &amp; Company LLC 在 3 月 9 日星期一重申了 “买入” 评级，并对肿瘤研究所股票发布了 5.00 美元的目标价格。最后，BTIG Research 在 3 月 9 日星期一重新发布了 “买入” 评级，并设定了 7.00 美元的目标价格。四位股票研究分析师对该股票给予了 “买入” 评级，一位分析师给予了 “卖出” 评级。根据 MarketBeat.com 的数据，肿瘤研究所目前的共识评级为 “适度买入”，共识目标价格为 7.00 美元。</p>
<p><strong>查看我们对肿瘤研究所的最新分析</strong></p>
<h2>肿瘤研究所公司简介</h2>
<p>（获取免费报告）</p>
<p>肿瘤研究所公司是一家肿瘤公司，在美国提供各种医学肿瘤服务。该公司通过三个部门运营：药房、患者服务和临床试验及其他。它提供医生服务、内部输液和药房、临床试验、放射治疗、门诊血液产品输血和患者支持服务，以及教育研讨会、支持小组和咨询服务。该公司还提供管理临床试验、姑息治疗项目、干细胞移植服务以及与非社区基础的学术和三级护理环境相关的其他护理交付模式；并为一系列制药和医疗器械公司进行临床试验。</p>
<h2>另见</h2>
<ul>
<li>我们更看好的五只股票，胜过肿瘤研究所</li>
<li>2 只软件股票将 AI 恐惧转化为基本面收益</li>
<li>代币接管：SEC 引发市场震荡</li>
<li>Target 展现出强劲，但分析师希望看到更多</li>
<li>NVIDIA 价格回调？别指望，业务正在加速</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VE9J?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VE9J"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资$1,000 在肿瘤研究所吗？</h2>
<p>在你考虑肿瘤研究所之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而肿瘤研究所并不在名单上。</p>
<p>虽然肿瘤研究所目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

标普生物技术 ETF - SPDR

纽交所高增长板生物技术指数 ETF - First Trust

动态生物技术与基因组 ETF - Invesco

纳斯达克生物科技指数 ETF - iShares Nasdaq

医药突破 ETF - ALPS

生物科技 ETF - VanEck Vectors

标普生物技术 3 倍做多 - Direxion

2 倍做多纳斯达克生物技术 ETF - ProShares

<p>Jorey Chernett，肿瘤研究所（NASDAQ:TOI）的主要股东，以每股 4.05 美元的价格购买了 5,000 股，总计 20,250 美元。此次交易后，Chernett 持有 10,534,358 股，价值约为 4266 万美元。这次收购使他的持股增加了 0.05%。该交易已按照规定向 SEC 披露，因为他持有公司 10% 或以上的股份</p>

<p>The Oncology Institute, Inc. (NASDAQ:TOI - Get Free Report) major shareholder Jorey Chernett acquired 5,000 shares of Oncology Institute stock in a transaction that occurred on Tuesday, May 19th. The shares were purchased at an average price of $4.05 per share, for a total transaction of $20,250.00. Following the completion of the purchase, the insider directly owned 10,534,358 shares of the company's stock, valued at $42,664,149.90. The trade was a 0.05% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities &amp; Exchange Commission, which is available through the SEC website. Large shareholders that own at least 10% of a company's shares are required to disclose their transactions with the SEC.</p>
<div class="lb-trans"><p>肿瘤研究所公司（NASDAQ:TOI - 获取免费报告）主要股东 Jorey Chernett 于 5 月 19 日星期二收购了 5,000 股肿瘤研究所股票。每股平均购买价格为 4.05 美元，总交易额为 20,250.00 美元。完成购买后，该内部人士直接持有公司 10,534,358 股股票，价值 42,664,149.90 美元。此次交易使其持股比例增加了 0.05%。该交易已在与证券交易委员会的法律文件中披露，相关信息可通过 SEC 网站获取。持有公司至少 10% 股份的大股东需向 SEC 披露其交易情况。</p>
</div><p>Get <strong>Oncology Institute</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>肿瘤研究所</strong> 的提醒：</p>
</div><p>Jorey Chernett also recently made the following trade(s):</p>
<div class="lb-trans"><p>Jorey Chernett 最近还进行了以下交易：</p>
</div><ul>
<li>On Wednesday, May 20th, Jorey Chernett purchased 33,500 shares of Oncology Institute stock. The shares were acquired at an average cost of $4.07 per share, for a total transaction of $136,345.00.</li>
<li>On Tuesday, May 19th, Jorey Chernett purchased 30,000 shares of Oncology Institute stock. The shares were acquired at an average cost of $4.09 per share, for a total transaction of $122,700.00.</li>
<li>On Thursday, April 9th, Jorey Chernett bought 20,000 shares of Oncology Institute stock. The shares were purchased at an average cost of $3.10 per share, for a total transaction of $62,000.00.</li>
<li>On Tuesday, March 24th, Jorey Chernett bought 125,000 shares of Oncology Institute stock. The stock was purchased at an average price of $3.11 per share, with a total value of $388,750.00.</li>
<li>On Friday, March 20th, Jorey Chernett bought 25,000 shares of Oncology Institute stock. The shares were acquired at an average cost of $3.35 per share, for a total transaction of $83,750.00.</li>
<li>On Tuesday, March 17th, Jorey Chernett bought 75,000 shares of Oncology Institute stock. The shares were acquired at an average cost of $3.42 per share, for a total transaction of $256,500.00.</li>
<li>On Monday, March 16th, Jorey Chernett purchased 60,985 shares of Oncology Institute stock. The shares were purchased at an average price of $3.29 per share, with a total value of $200,640.65.</li>
<li>On Friday, March 13th, Jorey Chernett bought 263,000 shares of Oncology Institute stock. The stock was bought at an average price of $2.92 per share, with a total value of $767,960.00.</li>
</ul>
<div class="lb-trans"><ul>
<li>5 月 20 日星期三，Jorey Chernett 购买了 33,500 股肿瘤研究所股票。每股平均成本为 4.07 美元，总交易额为 136,345.00 美元。</li>
<li>5 月 19 日星期二，Jorey Chernett 购买了 30,000 股肿瘤研究所股票。每股平均成本为 4.09 美元，总交易额为 122,700.00 美元。</li>
<li>4 月 9 日星期四，Jorey Chernett 购买了 20,000 股肿瘤研究所股票。每股平均成本为 3.10 美元，总交易额为 62,000.00 美元。</li>
<li>3 月 24 日星期二，Jorey Chernett 购买了 125,000 股肿瘤研究所股票。每股平均价格为 3.11 美元，总价值为 388,750.00 美元。</li>
<li>3 月 20 日星期五，Jorey Chernett 购买了 25,000 股肿瘤研究所股票。每股平均成本为 3.35 美元，总交易额为 83,750.00 美元。</li>
<li>3 月 17 日星期二，Jorey Chernett 购买了 75,000 股肿瘤研究所股票。每股平均成本为 3.42 美元，总交易额为 256,500.00 美元。</li>
<li>3 月 16 日星期一，Jorey Chernett 购买了 60,985 股肿瘤研究所股票。每股平均价格为 3.29 美元，总价值为 200,640.65 美元。</li>
<li>3 月 13 日星期五，Jorey Chernett 购买了 263,000 股肿瘤研究所股票。每股平均价格为 2.92 美元，总价值为 767,960.00 美元。</li>
</ul>
</div><h2>Oncology Institute Stock Down 0.8%</h2>
<div class="lb-trans"><h2>肿瘤研究所股票下跌 0.8%</h2>
</div><p>NASDAQ TOI traded down $0.04 during trading on Thursday, hitting $4.17. The company's stock had a trading volume of 358,184 shares, compared to its average volume of 1,889,279. The firm has a 50 day moving average price of $3.43 and a 200 day moving average price of $3.32. The firm has a market cap of $411.67 million, a P/E ratio of -11.26 and a beta of 0.33. The Oncology Institute, Inc. has a 52 week low of $2.02 and a 52 week high of $4.88.</p>
<div class="lb-trans"><p>在周四的交易中，NASDAQ TOI 下跌 0.04 美元，报 4.17 美元。该公司的股票交易量为 358,184 股，而其平均交易量为 1,889,279 股。该公司的 50 日移动平均价格为 3.43 美元，200 日移动平均价格为 3.32 美元。该公司的市值为 4.1167 亿美元，市盈率为-11.26，贝塔值为 0.33。肿瘤研究所公司的 52 周低点为 2.02 美元，52 周高点为 4.88 美元。</p>
</div><p>Oncology Institute (NASDAQ:TOI - Get Free Report) last released its quarterly earnings data on Thursday, May 7th. The company reported ($0.02) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.07) by $0.05. The firm had revenue of $147.44 million for the quarter, compared to the consensus estimate of $142.10 million. On average, equities analysts expect that The Oncology Institute, Inc. will post -0.2 earnings per share for the current year.</p>
<div class="lb-trans"><p>肿瘤研究所（NASDAQ:TOI - 获取免费报告）最近于 5 月 7 日星期四发布了季度财报。公司报告每股收益（EPS）为-0.02 美元，超出分析师一致预期的-0.07 美元，超出幅度为 0.05 美元。该季度的收入为 1.4744 亿美元，而一致预期为 1.4210 亿美元。分析师平均预计肿瘤研究所公司在当前年度的每股收益为-0.2 美元。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>机构资金流入和流出</h2>
</div><p>A number of institutional investors have recently added to or reduced their stakes in the company. Vanguard Group Inc. raised its stake in Oncology Institute by 6.2% during the 3rd quarter. Vanguard Group Inc. now owns 4,545,245 shares of the company's stock worth $15,863,000 after buying an additional 264,358 shares during the period. CenterBook Partners LP boosted its holdings in shares of Oncology Institute by 12.0% in the fourth quarter. CenterBook Partners LP now owns 3,029,312 shares of the company's stock worth $10,784,000 after acquiring an additional 324,662 shares during the period. Kanen Wealth Management LLC boosted its holdings in shares of Oncology Institute by 61.6% in the fourth quarter. Kanen Wealth Management LLC now owns 2,976,144 shares of the company's stock worth $10,712,000 after acquiring an additional 1,134,043 shares during the period. Balyasny Asset Management L.P. boosted its stake in Oncology Institute by 17.3% during the second quarter. Balyasny Asset Management L.P. now owns 2,518,337 shares of the company's stock valued at $5,163,000 after buying an additional 371,005 shares during the period. Finally, Josh Arnold Investment Consultant LLC boosted its stake in Oncology Institute by 1,104.3% during the fourth quarter. Josh Arnold Investment Consultant LLC now owns 2,459,809 shares of the company's stock valued at $8,757,000 after buying an additional 2,255,559 shares during the period. 36.86% of the stock is owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>一些机构投资者最近增加或减少了在该公司的持股。先锋集团（Vanguard Group Inc.）在第三季度将其在肿瘤研究所的持股增加了 6.2%。先锋集团目前持有 4,545,245 股该公司的股票，价值 15,863,000 美元，此前在该期间内又购买了 264,358 股。CenterBook Partners LP 在第四季度将其在肿瘤研究所的持股增加了 12.0%。CenterBook Partners LP 目前持有 3,029,312 股该公司的股票，价值 10,784,000 美元，此前在该期间内又收购了 324,662 股。Kanen Wealth Management LLC 在第四季度将其在肿瘤研究所的持股增加了 61.6%。Kanen Wealth Management LLC 目前持有 2,976,144 股该公司的股票，价值 10,712,000 美元，此前在该期间内又收购了 1,134,043 股。Balyasny Asset Management L.P.在第二季度将其在肿瘤研究所的持股增加了 17.3%。Balyasny Asset Management L.P.目前持有 2,518,337 股该公司的股票，价值 5,163,000 美元，此前在该期间内又购买了 371,005 股。最后，Josh Arnold Investment Consultant LLC 在第四季度将其在肿瘤研究所的持股增加了 1,104.3%。Josh Arnold Investment Consultant LLC 目前持有 2,459,809 股该公司的股票，价值 8,757,000 美元，此前在该期间内又购买了 2,255,559 股。36.86% 的股票由机构投资者和对冲基金持有。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>华尔街分析师预测增长</h2>
</div><p>Several brokerages have recently issued reports on TOI. Weiss Ratings reaffirmed a &#34;sell (d-)&#34; rating on shares of Oncology Institute in a research note on Monday, April 20th. B. Riley Financial increased their price target on Oncology Institute from $6.00 to $8.00 and gave the company a &#34;buy&#34; rating in a research report on Friday, March 13th. Needham &amp; Company LLC reaffirmed a &#34;buy&#34; rating and issued a $5.00 price objective on shares of Oncology Institute in a research report on Monday, March 9th. Finally, BTIG Research reissued a &#34;buy&#34; rating and set a $7.00 price target on shares of Oncology Institute in a report on Monday, March 9th. Four equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Oncology Institute currently has a consensus rating of &#34;Moderate Buy&#34; and a consensus target price of $7.00.</p>
<div class="lb-trans"><p>几家券商最近对 TOI 发布了报告。Weiss Ratings 在 4 月 20 日星期一的研究报告中重申了对肿瘤研究所股票的 “卖出（d-）” 评级。B. Riley Financial 在 3 月 13 日星期五将肿瘤研究所的目标价格从 6.00 美元提高至 8.00 美元，并给予该公司 “买入” 评级。Needham &amp; Company LLC 在 3 月 9 日星期一重申了 “买入” 评级，并对肿瘤研究所股票发布了 5.00 美元的目标价格。最后，BTIG Research 在 3 月 9 日星期一重新发布了 “买入” 评级，并设定了 7.00 美元的目标价格。四位股票研究分析师对该股票给予了 “买入” 评级，一位分析师给予了 “卖出” 评级。根据 MarketBeat.com 的数据，肿瘤研究所目前的共识评级为 “适度买入”，共识目标价格为 7.00 美元。</p>
</div><p><strong>View Our Latest Analysis on Oncology Institute</strong></p>
<div class="lb-trans"><p><strong>查看我们对肿瘤研究所的最新分析</strong></p>
</div><h2>Oncology Institute Company Profile</h2>
<div class="lb-trans"><h2>肿瘤研究所公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>The Oncology Institute, Inc, an oncology company, provides various medical oncology services in the United States. The company operates through three segments: Dispensary, Patient Services, and Clinical Trials &amp; Other. It offers physician services, in-house infusion and dispensary, clinical trial, radiation, outpatient blood product transfusion, and patient support services, as well as educational seminars, support groups, and counseling services. The company also provides managing clinical trials, palliative care programs, stem cell transplants services, and other care delivery models associated with non-community-based academic and tertiary care settings; and conducts clinical trials for a range of pharmaceutical and medical device companies.</p>
<div class="lb-trans"><p>肿瘤研究所公司是一家肿瘤公司，在美国提供各种医学肿瘤服务。该公司通过三个部门运营：药房、患者服务和临床试验及其他。它提供医生服务、内部输液和药房、临床试验、放射治疗、门诊血液产品输血和患者支持服务，以及教育研讨会、支持小组和咨询服务。该公司还提供管理临床试验、姑息治疗项目、干细胞移植服务以及与非社区基础的学术和三级护理环境相关的其他护理交付模式；并为一系列制药和医疗器械公司进行临床试验。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另见</h2>
</div><ul>
<li>Five stocks we like better than Oncology Institute</li>
<li>2 Software Stocks Turning AI Fears Into Fundamental Gains</li>
<li>The Token Takeover: SEC Triggers Market Quake</li>
<li>Target Shows Strengths, But Analysts Want to See More</li>
<li>NVIDIA Price Pullback? Don’t Count on It, Business Is Accelerating</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，胜过肿瘤研究所</li>
<li>2 只软件股票将 AI 恐惧转化为基本面收益</li>
<li>代币接管：SEC 引发市场震荡</li>
<li>Target 展现出强劲，但分析师希望看到更多</li>
<li>NVIDIA 价格回调？别指望，业务正在加速</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VE9J" alt="" original-src="https://www.marketbeat.com/scripts/InsiderTradesChart.ashx?Prefix=NASDAQ&amp;Symbol=TOI"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Oncology Institute Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资$1,000 在肿瘤研究所吗？</h2>
</div><p>Before you consider Oncology Institute, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑肿瘤研究所之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Oncology Institute wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而肿瘤研究所并不在名单上。</p>
</div><p>While Oncology Institute currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然肿瘤研究所目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Oncology Institute (NASDAQ:TOI) Major Shareholder Jorey Chernett Buys 5,000 Shares

Market Beat

Oncology Institute

Oncology Institute - CW22

肿瘤研究所（NASDAQ:TOI）的主要股东 Jorey Chernett 购买了 5,000 股股票